MARKI-MICROWAVE
27.9.2022 08:51:34 CEST | Business Wire | Press release
European Microwave Week – Marki Microwave®, innovator in the radio frequency and microwave industry for over 30 years, today announced the expansion of its millimeter wave (mmWave) portfolio with a series of leading-edge mixers featuring integrated local oscillator (LO) drivers. Ideal for space constrained applications requiring wide bandwidths and operation at mmWave frequencies, the integrated drive mixers reduce size, weight, power and cost (SWaP-C) while simplifying overall integration of the LO path for ease of use and optimized performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005833/en/
Marki Microwave's versatile, broadband double balanced mixers feature an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. (Graphic: Business Wire)
“For customers needing to realize the best performance in a small footprint with reduced design effort, our latest integrated drive mixers are game changers,” said Duncan Pilgrim, vice president of sales and marketing at Marki Microwave. “The designs deliver high performance across a wide bandwidth with reduced drive requirements, promising ease of use in a traditionally complex design space.”
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM are versatile, broadband double balanced mixers featuring an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. Unlike traditional industry solutions using discrete packages, which often suffer from subpar performance, Marki Microwave’s co-packaging utilizes optimal die technology for the amplifier and mixer functions. The new technique eliminates the need for a separate amplifier and mixer interface, minimizing design costs without sacrificing performance across the operating bandwidth. The new integrated drive mixers’ exceptional conversion loss and linearity combined with their compact footprint make the parts an ideal solution for high performance test and measurement, aerospace and defense, telecom infrastructure and satellite designs.
Availability
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM will be available in October in 3 x 4.6 mm QFN packages. Specifications subject to change without notice. For samples and sales information, contact sales@markimicrowave.com.
About Marki Microwave
For over 30 years, Marki Microwave has solved its customers’ most complex problems by creating a robust portfolio of performance shattering RF and microwave components. Founded in 1991 with the goal to develop the best mixers in the industry, Marki Microwave now has the highest performance portfolio of broadband mixers, spanning frequencies from 10 MHz to 130 GHz+ in die, surface mount and connectorized form factors. Today, Marki Microwave is a single source for high performance, broadband microwave products, supporting multiple form factors including die, surface mount and connectorized solutions for the entire RF block diagram. As demands from RF and microwave markets continue to evolve and the supply base consolidates, Marki Microwave remains dedicated to building beyond performance barriers, expanding its catalog and empowering the industry to build next-generation systems. For more information, visit www.markimicrowave.com.
© 2022. Marki Microwave, Inc. All Rights Reserved. Marki Microwave, the Marki logo, and T3 Mixer are trademarks or registered trademarks of Marki Microwave, Inc., in the U.S. and other countries. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
